Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,
▶ Netupitant is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
▶ Netupitant is predicted to increase the exposure to opioids
(methadone, sufentanil).oTheoretical
▶ Netupitant is predicted to increase the exposure to oxybutynin.
is predicted to increase the exposure to pazopanib.
▶ Netupitant is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil
▶ Netupitant is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Monitor or
adjust sildenafil dose with moderate inhibitors of CYP3A4,
▶ Netupitant is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical
▶ Netupitant is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors
▶ Netupitant is predicted to increase the exposure to pimozide.
▶ Netupitant is predicted to increase the exposure to quetiapine.
is predicted to increase the exposure to ranolazine.
is predicted to increase the exposure to ribociclib.
▶ Rifampicin is predicted to decrease the exposure to netupitant.
is predicted to increase the exposure to ruxolitinib.
▶ Netupitant is predicted to increase the exposure to saxagliptin.
▶ Netupitant increases the concentration of sirolimus. Monitor
▶ Netupitant is predicted to increase the exposure to SSRIs
(dapoxetine). Adjust dapoxetine dose with moderate inhibitors
of CYP3A4, p. 821.oTheoretical
▶ St John’s Wort is predicted to decrease the exposure to
▶ Netupitant is predicted to increase the exposure to statins
(atorvastatin). Monitor and adjust dose.rStudy
▶ Netupitant is predicted to increase the exposure to statins
(simvastatin). Use with caution and adjust simvastatin dose,
is predicted to increase the exposure to sunitinib.
▶ Netupitant is predicted to increase the concentration of
▶ Netupitant is predicted to increase the exposure to taxanes
▶ Netupitant slightly increases the exposure to taxanes
▶ Netupitant is predicted to increase the exposure to taxanes
▶ Netupitant is predicted to increase the concentration of
▶ Netupitant is predicted to increase the exposure to tezacaftor.
Adjust tezacaftor with ivacaftor p. 295 dose with moderate
▶ Netupitant given with a potent CYP2C19 inhibitor is predicted
to increase the exposure to tofacitinib. Adjust tofacitinib dose,
▶ Netupitant is predicted to increase the exposure to tolterodine.
▶ Netupitant is predicted to increase the exposure to tolvaptan.
Manufacturer advises caution or adjust tolvaptan dose with
moderate inhibitors of CYP3A4, p. 669.oStudy
is predicted to increase the exposure to trazodone.
▶ Netupitant is predicted to increase the exposure to ulipristal.
Avoid if used for uterine fibroids.oStudy
▶ Netupitant is predicted to increase the exposure to venetoclax.
Avoid or adjust dose—consult product literature.rStudy
▶ Netupitant is predicted to increase the exposure to vinca
▶ Netupitant is predicted to increase the exposure to zopiclone.
Neuromuscular blocking drugs, non-depolarising → see TABLE 6
p. 1376 (bradycardia), TABLE 20 p. 1379 (neuromuscular blocking effects)
neuromuscular blocking drugs, non-depolarising.
Theoretical → Also see TABLE 6 p. 1376
▶ Antiepileptics (carbamazepine) are predicted to decrease the
effects of (but acute use increases the effects of) neuromuscular
blocking drugs, non-depolarising (atracurium, cisatracurium,
. Monitor and adjust dose.o ▶ Antiepileptics (fosphenytoin, phenytoin) decrease the effects of
(but acute use increases the effects of) neuromuscular blocking
drugs, non-depolarising (atracurium, cisatracurium,
pancuronium, rocuronium).oStudy
▶ Clindamycin increases the effects of neuromuscular blocking
drugs, non-depolarising.rAnecdotal
▶ Corticosteroids are predicted to decrease the effects of
neuromuscular blocking drugs, non-depolarising
1500 Netupitant — Neuromuscular blocking drugs, non-depolarising BNF 78
▶ Pancuronium is predicted to increase the risk of cardiovascular
side-effects when given with digoxin.rAnecdotal
▶ Irinotecan is predicted to decrease the effects of
neuromuscular blocking drugs, non-depolarising
.o ▶ Intravenous magnesium increases the effects of neuromuscular
blocking drugs, non-depolarising.oStudy
▶ Metoclopramide is predicted to increase the effects of
neuromuscular blocking drugs, non-depolarising
.o ▶ Penicillins (piperacillin) increase the effects of neuromuscular
blocking drugs, non-depolarising.oStudy
▶ SSRIs potentially increase the risk of prolonged
neuromuscular blockade when given with mivacurium.
▶ Nevirapine is predicted to decrease the exposure to
antiarrhythmics (dronedarone).rTheoretical
▶ Nevirapine is predicted to decrease the concentration of
antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) and antiepileptics (carbamazepine,
fosphenytoin, phenobarbital, phenytoin, primidone) are
predicted to decrease the concentration of
▶ Antifungals, azoles (fluconazole) slightly to moderately increase
the exposure to nevirapine.oStudy
▶ Nevirapine is predicted to decrease the exposure to antifungals,
azoles (isavuconazole). Avoid.rTheoretical
▶ Nevirapine moderately decreases the exposure to antifungals,
azoles (itraconazole). Avoid and for 14 days after stopping
▶ Nevirapine moderately decreases the exposure to antifungals,
azoles (ketoconazole). Avoid.rStudy
▶ Nevirapine is predicted to decrease the exposure to antifungals,
azoles (voriconazole) and antifungals, azoles (voriconazole)
nevirapine. Monitor and adjust dose.
is predicted to decrease the exposure to aprepitant.
is predicted to decrease the exposure to axitinib.
▶ Nevirapine is predicted to decrease the exposure to
is predicted to decrease the exposure to nevirapine.
▶ Nevirapine is predicted to decrease the exposure to bosutinib.
▶ Nevirapine is predicted to decrease the exposure to brigatinib.
▶ Nevirapine is predicted to decrease the exposure to
▶ Nevirapine is predicted to decrease the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
▶ Nevirapine is predicted to decrease the exposure to calcium
channel blockers (diltiazem, verapamil).oTheoretical
▶ Nevirapine is predicted to decrease the exposure to
cariprazine. Avoid.rTheoretical
▶ Nevirapine is predicted to decrease the concentration of
caspofungin. Adjust dose.oTheoretical
▶ Nevirapine is predicted to decrease the concentration of
▶ Nevirapine is predicted to decrease the exposure to cobicistat.
▶ Nevirapine is predicted to decrease the exposure to
cobimetinib. Avoid.rTheoretical
▶ Nevirapine is predicted to decrease the efficacy of combined
hormonal contraceptives. For FSRH guidance, see
Contraceptives, interactions p. 794.rStudy
▶ Nevirapine potentially alters the anticoagulant effect of
▶ Nevirapine is predicted to decrease the exposure to crizotinib.
▶ Nevirapine is predicted to decrease the exposure to dasabuvir.
is predicted to decrease the exposure to dasatinib.
▶ Nevirapine is predicted to decrease the efficacy of desogestrel.
Contraceptives, interactions p. 794.
▶ Nevirapine decreases the exposure to dolutegravir. Adjust
▶ Nevirapine is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
decreases the concentration of efavirenz. Avoid.
▶ Nevirapine is predicted to moderately decrease the exposure
is predicted to decrease the exposure to eliglustat.
▶ Nevirapine is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
▶ Enzalutamide is predicted to decrease the exposure to
is predicted to decrease the effects of ergotamine.
is predicted to decrease the exposure to erlotinib.
▶ Nevirapine is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Nevirapine is predicted to decrease the exposure to etravirine.
▶ Nevirapine is predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶ Nevirapine is predicted to decrease the exposure to
▶ Nevirapine is predicted to decrease the exposure to gefitinib.
▶ Nevirapine is predicted to decrease the exposure to
▶ Nevirapine is predicted to markedly decrease the exposure to
▶ Nevirapine is predicted to decrease the concentration of
guanfacine. Adjust dose.oTheoretical
▶ Nevirapine decreases the exposure to HIV-protease inhibitors.
Refer to specialist literature.oStudy
▶ Nevirapine is predicted to decrease the effects of hormone
replacement therapy.oAnecdotal
▶ Nevirapine is predicted to decrease the exposure to idelalisib.
No comments:
Post a Comment
اكتب تعليق حول الموضوع